Brokers Set Expectations for Disc Medicine Opco Inc’s Q1 2023 Earnings (NASDAQ:IRON)

Posted by on Apr 27th, 2023

Disc Medicine Opco Inc (NASDAQ:IRON – Get Rating) – Equities researchers at Lifesci Capital issued their Q1 2023 earnings per share (EPS) estimates for shares of Disc Medicine Opco in a research note issued to investors on Monday, April 24th. Lifesci Capital analyst R. Katkhuda anticipates that the company will earn ($0.79) per share for the quarter. Lifesci Capital currently has a “Outperform” rating on the stock. The consensus estimate for Disc Medicine Opco’s current full-year earnings is ($2.69) per share. Lifesci Capital also issued estimates for Disc Medicine Opco’s Q2 2023 earnings at ($0.82) EPS, Q3 2023 earnings at ($0.85) EPS, Q4 2023 earnings at ($0.87) EPS, FY2023 earnings at ($3.34) EPS and FY2024 earnings at ($2.88) EPS.

Other equities analysts have also recently issued research reports about the company. BMO Capital Markets started coverage on Disc Medicine Opco in a report on Thursday, March 23rd. They issued an “outperform” rating and a $40.00 price objective for the company. Wedbush assumed coverage on Disc Medicine Opco in a research note on Tuesday, January 3rd. They set an “outperform” rating and a $30.00 target price for the company. SVB Securities initiated coverage on Disc Medicine Opco in a report on Tuesday, February 28th. They issued an “outperform” rating and a $36.00 price objective for the company. Morgan Stanley started coverage on shares of Disc Medicine Opco in a research report on Thursday, April 20th. They set an “overweight” rating and a $37.00 price target on the stock. Finally, Stifel Nicolaus started coverage on shares of Disc Medicine Opco in a research report on Thursday, April 20th. They issued a “buy” rating and a $37.00 price target on the stock. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $36.00.

Disc Medicine Opco Stock Performance

IRON stock opened at $31.69 on Wednesday. The business’s 50-day moving average price is $23.78. The company has a market cap of $602.11 million, a PE ratio of -3.17 and a beta of -0.27. Disc Medicine Opco has a 1 year low of $11.80 and a 1 year high of $32.85.

Institutional Investors Weigh In On Disc Medicine Opco

Several large investors have recently modified their holdings of the stock. Citigroup Inc. purchased a new position in Disc Medicine Opco in the 4th quarter valued at approximately $101,000. UBS Group AG purchased a new position in Disc Medicine Opco in the 4th quarter valued at approximately $142,000. Boxer Capital LLC purchased a new position in Disc Medicine Opco in the 4th quarter valued at approximately $176,000. Renaissance Technologies LLC purchased a new position in Disc Medicine Opco in the 4th quarter valued at approximately $258,000. Finally, Millennium Management LLC purchased a new position in Disc Medicine Opco in the 4th quarter valued at approximately $294,000. Hedge funds and other institutional investors own 75.42% of the company’s stock.

Disc Medicine Opco Company Profile

(Get Rating)

Disc Medicine, Inc, a clinical-stage biotechnology company, engages in discovering, developing, and commercializing novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis.

Featured Articles

Receive News & Ratings for Disc Medicine Opco Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Disc Medicine Opco and related companies with MarketBeat.com's FREE daily email newsletter.